Tag Archives: sNDA

AstraZeneca announces that FDA accepted sNDA and granted Priority Review for BRILINTA® (ticagrelor) for patients with history of heart attack

LONDON, 4-5-2015 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. … Read the full press release